CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 439 filers reported holding CRISPR THERAPEUTICS AG in Q3 2022. The put-call ratio across all filers is 0.94 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,778,147 | -68.8% | 127,300 | -61.5% | 0.09% | -72.9% |
| Q2 2023 | $18,543,042 | +1724.7% | 330,300 | +1221.2% | 0.33% | +1950.0% |
| Q4 2022 | $1,016,250 | -76.1% | 25,000 | -61.5% | 0.02% | -72.9% |
| Q3 2022 | $4,248,000 | -12.6% | 65,000 | -18.8% | 0.06% | -11.9% |
| Q2 2022 | $4,861,000 | +93.5% | 80,000 | +100.0% | 0.07% | +123.3% |
| Q1 2022 | $2,512,000 | -24.0% | 40,000 | -8.3% | 0.03% | -21.1% |
| Q4 2021 | $3,305,000 | -75.1% | 43,600 | -46.8% | 0.04% | -78.0% |
| Q2 2021 | $13,260,000 | +156.0% | 81,900 | +92.7% | 0.17% | +55.9% |
| Q1 2021 | $5,179,000 | -59.7% | 42,500 | -75.7% | 0.11% | -74.1% |
| Q2 2020 | $12,861,000 | +203.3% | 175,000 | +75.0% | 0.43% | +78.3% |
| Q1 2020 | $4,241,000 | -30.4% | 100,000 | 0.0% | 0.24% | +17.1% |
| Q4 2019 | $6,091,000 | +854.7% | 100,000 | +594.4% | 0.20% | +485.7% |
| Q3 2018 | $638,000 | -24.7% | 14,400 | 0.0% | 0.04% | -47.0% |
| Q2 2018 | $847,000 | – | 14,400 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 3,608,874 | $160,053,562,000 | 54.44% |
| Abingworth LLP | 1,237,202 | $54,858,000 | 32.62% |
| NEA Management Company, LLC | 2,090,678 | $92,722,000 | 4.00% |
| New Leaf Venture Partners, L.L.C. | 444,708 | $19,723,000 | 3.59% |
| EcoR1 Capital, LLC | 500,000 | $22,175,000 | 2.00% |
| ARK Investment Management | 1,453,590 | $64,467,000 | 1.95% |
| CLOUGH CAPITAL PARTNERS L P | 337,731 | $14,978,000 | 1.41% |
| Casdin Capital, LLC | 220,000 | $9,757,000 | 1.19% |
| Valiant Capital Management, L.P. | 271,700 | $12,050,000 | 1.07% |
| Monashee Investment Management LLC | 110,000 | $4,879,000 | 1.03% |